Minerva Neurosciences Future Growth

Future criteria checks 0/6

Minerva Neurosciences is forecast to grow earnings and revenue by 44.2% and 88% per annum respectively while EPS is expected to grow by 37.4% per annum.

Key information

44.2%

Earnings growth rate

37.4%

EPS growth rate

Biotechs earnings growth	28.5%
Revenue growth rate	88.0%
Future return on equity	n/a
Analyst coverage	Low
Last updated	06 Nov 2024

Recent future growth updates

Recent updates

Minerva says FDA declined to accept marketing application for schizophrenia drug

Oct 17

Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Jan 26

Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation

Oct 02

Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares

Mar 03

What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition

Jan 27

We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate

Dec 23

A Potential Trade Arises On Minerva

Dec 09

A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns

Nov 18

Minerva Neurosciences EPS beats by $0.03

Nov 02

Earnings and Revenue Growth Forecasts

NasdaqCM:NERV - Analysts future estimates and past financials data (USD Millions)
Date	Revenue	Earnings	Free Cash Flow	Cash from Op	Avg. No. Analysts
12/31/2026	N/A	-46	N/A	N/A	1
12/31/2025	N/A	-30	N/A	N/A	1
12/31/2024	N/A	-2	N/A	N/A	1
9/30/2024	N/A	-3	-20	-20	N/A
6/30/2024	N/A	-34	-21	-21	N/A
3/31/2024	N/A	-32	-21	-21	N/A
12/31/2023	N/A	-30	-15	-15	N/A
9/30/2023	N/A	-28	-13	-13	N/A
6/30/2023	N/A	-27	-18	-18	N/A
3/31/2023	N/A	-29	-19	-19	N/A
12/31/2022	N/A	-32	-25	-25	N/A
9/30/2022	N/A	-47	-25	-25	N/A
6/30/2022	N/A	-49	-24	-24	N/A
3/31/2022	N/A	-51	-25	-25	N/A
12/31/2021	N/A	-50	-25	-25	N/A
9/30/2021	N/A	-36	-27	-27	N/A
6/30/2021	N/A	-35	-28	-28	N/A
3/31/2021	41	5	-30	-30	N/A
12/31/2020	41	2	-34	-34	N/A
9/30/2020	41	-21	-41	-41	N/A
6/30/2020	41	-27	-40	-40	N/A
3/31/2020	N/A	-69	-43	-43	N/A
12/31/2019	N/A	-72	-43	-43	N/A
9/30/2019	N/A	-55	-39	-39	N/A
6/30/2019	N/A	-54	-40	-40	N/A
3/31/2019	N/A	-54	-41	-41	N/A
12/31/2018	N/A	-50	-42	-42	N/A
9/30/2018	N/A	-37	-41	-41	N/A
6/30/2018	N/A	-36	N/A	-6	N/A
3/31/2018	N/A	-33	N/A	-2	N/A
12/31/2017	N/A	-32	N/A	3	N/A
9/30/2017	N/A	-41	N/A	3	N/A
6/30/2017	N/A	-38	N/A	-26	N/A
3/31/2017	N/A	-34	N/A	-26	N/A
12/31/2016	N/A	-31	N/A	-26	N/A
9/30/2016	N/A	-30	N/A	-23	N/A
6/30/2016	N/A	-28	N/A	-24	N/A
3/31/2016	N/A	-29	N/A	-25	N/A
12/31/2015	N/A	-27	N/A	-24	N/A
9/30/2015	N/A	-26	N/A	-23	N/A
6/30/2015	N/A	-47	N/A	-44	N/A
3/31/2015	N/A	-60	N/A	-40	N/A
12/31/2014	N/A	-57	N/A	-36	N/A
9/30/2014	N/A	-52	N/A	-32	N/A
6/30/2014	N/A	-25	N/A	-5	N/A
3/31/2014	N/A	-6	N/A	-3	N/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: NERV is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: NERV is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: NERV is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: NERV is forecast to have no revenue next year.

High Growth Revenue: NERV is forecast to have no revenue next year.

Earnings per Share Growth Forecasts

Future Return on Equity

Future ROE: Insufficient data to determine if NERV's Return on Equity is forecast to be high in 3 years time

Minerva Neurosciences Future Growth

Future criteria checks 0/6

Key information

Recent future growth updates

Price target decreased to US$6.67

Price target increased to US$8.33

Consensus revenue estimates fall to US$400.0k

Consensus forecasts updated

Analysts update estimates

Recent updates

Minerva Neurosciences, Inc., Annual General Meeting, Dec 05, 2024

Minerva Neurosciences Receives Second Written Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities Requirement under Nasdaq Listing Rule 5550(b)(2)

Minerva Neurosciences Receives Notice from Nasdaq Regarding Non-Compliance with the Minimum Market Value of Listed Securities Requirement Nasdaq's Listing Rule 5550(b)(2)

Minerva Neurosciences, Inc., Annual General Meeting, Sep 27, 2023

Minerva Neurosciences, Inc. announced that it expects to receive $19.999994 million in funding from Frazier Healthcare Partners, Boehringer Ingelheim International GmbH

Nasdaq Determines to Delist Minerva Neurosciences' Securities from The Nasdaq Capital Market

Minerva Neurosciences, Inc. to Report Q1, 2023 Results on May 15, 2023

Minerva Neurosciences, Inc. Announces Board Changes

Minerva Neurosciences, Inc. Announces Update on its New Drug Application (NDA) for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva Neurosciences Receives Non-Compliance Notice from The Nasdaq Stock Market LLC

Minerva Neurosciences, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Minerva Neurosciences, Inc. Receives Refusal to File Letter from FDA for its New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Minerva says FDA declined to accept marketing application for schizophrenia drug

Minerva Neurosciences: Biotech On The Move

Minerva Neurosciences, Inc. Submits New Drug Application to Fda for Roluperidone for the Treatment of Negative Symptoms in Patients with Schizophrenia

Minerva stock rises on filing for FDA approval of schizophrenia therapy

We're Hopeful That Minerva Neurosciences (NASDAQ:NERV) Will Use Its Cash Wisely

Insufficient new directors

Minerva Neurosciences Provides Update from Type C Meeting with FDA and Next Steps in Preparation for Submission of New Drug Application for Roluperidone for the Treatment of Negative Symptoms in Schizophrenia

Price target decreased to US$6.67

Minerva Neurosciences, Inc. Announces Publication of Roluperidone Phase 3 Study Results in Schizophrenia Bulletin

Is Minerva Neurosciences (NASDAQ:NERV) In A Good Position To Deliver On Growth Plans?

Price target increased to US$8.33

Here's Why We're Not Too Worried About Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Situation

Consensus revenue estimates fall to US$400.0k

Minerva Neurosciences, Inc.(NasdaqGM:NERV) dropped from Russell 3000E Growth Index

Investor sentiment improved over the past week

Consensus forecasts updated

Minerva Neurosciences, Inc. Announces the Results of the Phase 3 Trial of Roluperidone for the Treatment of Negative Symptoms of Schizophrenia Following the Completion of the 40-Week Open-Label Extension

Investor sentiment deteriorated over the past week

Analysts update estimates

Earnings beat expectations, revenue disappoints

Minerva Neurosciences' (NASDAQ:NERV) Shareholders Are Down 59% On Their Shares

Minerva Neurosciences, Inc. to Report Q4, 2020 Results on Mar 08, 2021

What You Need To Know About Minerva Neurosciences, Inc.'s (NASDAQ:NERV) Investor Composition

Bernstein Liebhard LLP Reminds Investors in SPLK, NAK, and NERV of Filing Deadlines

Bragar Eagel & Squire, P.C. Reminds Investors That Class Action Lawsuits Have Been Filed Against Minerva Neurosciences, Inc

We're Keeping An Eye On Minerva Neurosciences' (NASDAQ:NERV) Cash Burn Rate

New 90-day low: US$2.58

Block & Leviton LLP Announces That It Has Filed A Lawsuit Against Minerva Neurosciences, Inc. for Securities Fraud

A Potential Trade Arises On Minerva

A Look At Minerva Neurosciences' (NASDAQ:NERV) Share Price Returns

New 90-day high: US$3.59

Earnings miss expectations

Minerva Neurosciences EPS beats by $0.03

Minerva Neurosciences, Inc. to Report Q3, 2020 Results on Nov 02, 2020

New 90-day low - US$3.21

Minerva Neurosciences, Inc.(NasdaqGM:NERV) dropped from Russell Microcap Value Index

Earnings and Revenue Growth Forecasts

Analyst Future Growth Forecasts

Earnings per Share Growth Forecasts

Future Return on Equity

Discover growth companies